Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Initiates Coverage On ZimVie with Neutral Rating

Guggenheim analyst Chris Pasquale initiates coverage on ZimVie (NASDAQ:ZIMV) with a Neutral rating.

byBenzinga Newsdesk

March 18, 2022

1 minute read

Guggenheim analyst Chris Pasquale initiates coverage on ZimVie (NASDAQ:ZIMV) with a Neutral rating.

Stifel Downgrades Scientific Games to Hold, Raises Price Target to $90

By Benzinga Newsdesk

Today, 10:49 PM

Stifel downgrades Scientific Games (NASDAQ:SGMS) from Buy to Hold and raises the price target from $84 to $90.

SGMS

FDA
News

UPDATE: Pfizer Chief Scientific Officer Says Does Not See Needing To Replace Current Version Of COVID-19 Vaccine To Account For Delta Variant

By Benzinga Newsdesk

Today, 10:49 PM

-Reuters

BNTX

Progyny Q2 EPS $0.19 Beats $0.08 Estimate, Sales $128.65M Miss $129.31M Estimate

By Benzinga Newsdesk

Today, 10:49 PM

Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.08 by 137.5 percent. This is a 1050 percent increase over losses of $(0.02) per share from the same

PGNY

Needham Maintains Buy on C3.ai, Lowers Price Target to $103

By Benzinga Newsdesk

Today, 10:49 PM

Needham analyst Jack Andrews maintains C3.ai (NYSE:AI) with a Buy and lowers the price target from $122 to $103.

Guggenheim Initiates Coverage On ZimVie with Neutral Rating

Related Posts

Stifel Downgrades Scientific Games to Hold, Raises Price Target to $90

UPDATE: Pfizer Chief Scientific Officer Says Does Not See Needing To Replace Current Version Of COVID-19 Vaccine To Account For Delta Variant

Progyny Q2 EPS $0.19 Beats $0.08 Estimate, Sales $128.65M Miss $129.31M Estimate

Needham Maintains Buy on C3.ai, Lowers Price Target to $103